# Page 1
Revised administrative approval for procurement of Ivlg (for MSI C) required for COVID-19 preventive measures from Supplementary Demand Grant for 2021-22 under Epidemic Disease Control Programme (TIPS 22104286).
The Government of Maharashtra
the Department of Public Health
Government Resolution No: PRASHAMA-1221/ PR No. 142/ HEALTH-8
10th Floor, Hospital Building
New Ministry, Mumbai- 400001.
Date of release: November 1, 2021
Read: 1) Government Decision, Public Health Department No. No: Prashama- 1221/ PR No. 142/ Health- 8, Dy. 13.07.2021 2) Director, Health Services, Pune vide letter No. 22382-83/2021 regarding revised administrative approval for procurement of drugs/ COVID-19/ Control Room, Pune. 21.09.2021 and dt.
11.10.2021 3) Consent note dated 21.09.2021 from the Commissioner (Health Services) and Mission Director, National Health Mission, Mumbai.
Preamble: As proposed by the Director, Health Services, Pune vide letter dated 11.10.2021, the procurement of drug Ivlg (for MSI C) required for COVID-19 preventive measures is estimated to be done within the limit of subsidy in Supplementary Demand sanctioned under head 22104286 during the financial year 2021-22 at a cost of Rs. A revised administrative sanction of Rs. 21,00,00, 000/- (Rupees Twenty One Crores only) is under consideration of the Government.
Government Decision: Reference No. As per the government decision, administrative approval has been granted for the procurement of the drug Ivlg (for MSI C), which is required for the treatment of COVID-19.
The Director, Health Services, Pune Office vide their letter dated 21.09.2021 and vide No. As per the proposal submitted vide letter dated 11.10.2021, based on the price received from the procurement cell of Haffkine Corporation at the end of the physical bidding process, the estimated cost of the said drugs is Rs. Revised administrative approval is being accorded for procurement of 21,00,00, 000/- (Rupees Twenty One Crore only).
Expenditure for the said procurement is estimated to be Rs. 21,00,00, 000/- (Rupees Twenty One Crore only) during the financial year 2021-22 under Epidemic Disease Control Programme Account Head 22104286.
# Page 2
Government Resolution No: PRASHAMA-1221/ PR No. 142/ Arogya 8
The available supplementary demand will be met from the amount transferred from the grant to the Haffkine Purchase Cell. Accordingly, the statement for revised administrative approval for procurement of drug Ivlg (for MSI C) as indicated in the table below is as follows:
Details of Subsidy/ Purchase
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| Sr. No          | Name of Item | Approx. Rate per Unit (Rs.) | Approx. Quantity to be Procured (Nos.) | Approx.Amou nt of Procured (Rs.) | Rate Received through E-Tender@ HBPCL (Rs.) | Actual Amount Required as per E Tender Rate (Rs.)                   | Budget Source |
| Ivlg (for MSI - | 6000/        | 25000                       | 15,00,00,000/                          | 8400/                            | 21,00,00,000/                               | Epidemic Control Programme 22104286 (Proposed Supp. Demand 2021-22) |
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
In pursuance of the above proposal, the Director, Health Services, Pune Office vide their proposal dated 21.09.2021 has certified the certificates (Annexure-A) and utilization certificate to be submitted for the proposal for revised administrative approval for procurement of the drug Ivlg (for MSIC) in the wake of COVID-19 in the State for therapeutic and preventive measures in view of the possible wave of COVID-19.
The Commissioner, Health Services, Commissionerate, Mumbai vide his note dated 21.09.2021 has approved the proposal for procurement of drug Ivlg (for MSI C) for COVID-19 at an estimated cost of Rs. 21,00,00, 000/- (Rupees Twenty One Crores only) for the purpose of preventive and curative measures in view of possible COVID-19 wave.
As proposed by the Director, Health Services, Pune, the procurement of the drug Ivlg (for MSI C) required for COVID-19 preventive measures from the Supplementary Demand Grant for the year 2021-22 to the health institutions in the state should be done within the limits of the subsidy available. Director, Health Services, Pune. 21.09.2021 and dt.
The expenditure for the said procurement as mentioned in the Certificate (Annexure-A) submitted as per the proposal dated 11.10.2021 is estimated to be Rs. 21,00,00, 000/- (Rupees Twenty One Crore only) during the financial year 2021-22 from the Supplementary Demand Grant available under Epidemic Control Programme Account Head 22104286. The revised administrative approval is being granted subject to the terms of the Government Resolution dated 13.07.2021.
Government Resolution, Department of Finance, vide No. 2013/ Q. No. 30/13/ Regulations, Part-II, dated 17th April, 2015, in the Financial Powers Rules, 1978, Part-I, Sub-Section-II, Section 4, Rule No. Page 2 of 3 to buy tools, retail tool materials and activity kits under 7
# Page 3
Government Resolution No: PRASHAMA-1221/ PR No. 142/ HEALTH-8
The proposal is being approved as per the authority vested with the administrative department for approval.